Evidence-based Prevention & Treatment
Options for Emerging Heroin Use in a Public Health Framework

Benedikt Fischer, PhD
Professor, CIHR/PHAC Chair in Applied Public Health & MSFHR Senior Scholar
Faculty of Health Sciences & School of Criminology,
I/Director, Centre for Applied Research in Mental Health and Addictions (CARMHA)
Simon Fraser University, Vancouver, Canada
Senior Scientist, Centre for Addiction and Mental Health (CAMH), Toronto
Adjunct Scientist, BC Centre for Disease Control (BCCDC), Vancouver
bfischer@sfu.ca

CICAD Meeting, Washington, DC, 04 May 2010
Heroin Use – why concern for public health?

• Major risks/harms:
• **Morbidity:** Infectious disease transmission, including HIV/HCV, especially if H is used by injection (rather than smoked)
• Morbidity/InfDis risks greatly enhanced if heroin is used a) in risky environments and b) in conjunction with other drugs (e.g., stimulants => ‘bingeing’)
• **Mortality:** Accidental overdose deaths, e.g. due to variable substance purity/contamination
• **Crime:** H is bought on black markets, and associated with substantial acquisition (e.g., property crime, sex work etc.) crime

Targeted Prevention for Heroin Use

• What to do? => depends on socio-epidemiological situation of use
• If heroin is largely used by non-injection smoked, key focus ought to be on preventing transition to injecting as key morbidity/mortality risk
• Few studies of brief interventions/educational outreach for maintenance of/switch to non-injection routes suggesting short-term benefits (but limited strength of evidence)
• For injection users, clear & strong evidence that a) easily accessible and b) well-run needle exchange programs will lower infectious disease transmission risk and incidence
Treatment options

- Opioid maintenance treatment (OMT) as primary treatment response in virtually all Western countries, and increasingly elsewhere
- Methadone: Oral opioid agonist treatment, in practical use and researched in North America since 1960s; widely available in numerous countries, as far as China & Iran
- Buprenorphine: Newer oral agonist/antagonist (Bup/Naloxone combo) => preferable for more stable populations and more diversion/abuse resistant; available in North America, France, others
- Both Methadone and Buprenorphine added to the WHO’s ‘List of Essential Medicines’ in 2005 supported by WHO, ONDCP, UNAIDS
- Medical Heroin Prescription: Injection or oral options; examined by large-scale clinical trials in CH, NL, GER, CAN, and in very limited use for high-risk and treatment refractory H-user populations

Benefits of OMT (see NIDA, Cochrane group, NIH Consensus Conf/JAMA, BMJ, Lancet => pub details on request)

- … among opioid users successfully attracted and retained into OMT:
  - Reduction of HIV infection risk and incidence
  - Reduction of illicit opiate drug use
  - Reduction of overdose risks & fatalities
  - Reduction of drug-related crime
  - Improvement of physical and mental health status & Quality of Life indicators
  - Cost-beneficial and cost-effective
- …also implies that OMT constitutes both effective treatment and prevention, especially if provided to users at an early stage of use
Challenges for OMT

- Appeals/attracts only limited proportion of H users -> in ‘optimized’ systems, max. 50% of users
- Structures/practices of delivery: Broad OMT reach & accessibility cannot be achieved by specialized clinics but require integration of OMT into community-based health care services (e.g., GP offices, community health centres, local pharmacies) => requires broad training
- Broad OMT availability & community dispensing can facilitate diversion, i.e. methadone can become commodity on illicit drug markets => restrictions/control need to be balanced with public health aims
- In several countries (incl. US & CAN), prescription opioids (e.g., oxycodone, hydromorphone, codeine) have replaced heroin as drug of choice among street users => new challenge for prevention & treatment interventions (especially in ‘PO rich countries’)
Drug-related Deaths in Switzerland, 1987-2007


Numbers of Newly Diagnosed HIV-infections by Principal Source of Infection, Switzerland, 1988 - 2008
